Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.
When B.C. municipalities forced the province to delay controversial changes to the Heritage Conservation Act in September, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback